Jefferies Initiates Coverage of Nuvalent (NUVL) with Buy Recommendation

7d ago, source: Fintel on MSN

Fintel reports that on April 17, 2024, Jefferies initiated coverage of Nuvalent (NasdaqGS:NUVL) with a Buy recommendation.

Jefferies starts Nuvalent at buy, cites lung cancer drug candidates

on MSN ago, source:

Jefferies started coverage of Nuvalent (NUVL) with a buy rating, citing the company’s two lead drug assets for non-small cell ...

Nuvalent (NUVL) Price Target Increased by 6.08% to 104.19

8d ago, source: Fintel on MSN

The average one-year price target for Nuvalent (NasdaqGS:NUVL) has been revised to 104.19 / share. This is an increase of 6.08% from the prior estimate of 98.21 dated March 28, 2024. The price target ...

Revolution Medicines: An Expensive Shot At A Massive Market Opportunity

13d ago, source:

Revolution is pioneering a unique precision-based approach to developing oncology drugs that target the RAS pathway. Read why ...